With a one year PEG ratio of 199.86, Emergent BioSolutions Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 86.08% of US stocks.
EBS's current price/earnings ratio is 53.35, which is higher than 91.41% of US stocks with positive earnings.
Revenue growth over the past 12 months for Emergent BioSolutions Inc comes in at 41.36%, a number that bests 87.2% of the US stocks we're tracking.
If you're looking for stocks that are quantitatively similar to Emergent BioSolutions Inc, a group of peers worth examining would be ON, CSGS, CIEN, AVAV, and AEIS.
Emergent BioSolutions is a biopharmaceutical company which develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company was founded in 1998 and is based in Gaithersburg, Maryland.
EBS Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Emergent BioSolutions Inc. To summarize, we found that Emergent BioSolutions Inc ranked in the 39th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Emergent BioSolutions Inc ended up being:
Its compound free cash flow growth rate, as measured over the past 5.79 years, is 0.21% -- higher than 67.86% of stocks in our DCF forecasting set.
Emergent BioSolutions Inc's effective tax rate, as measured by taxes paid relative to net income, is at 17 -- greater than 65.52% of US stocks with positive free cash flow.
Relative to other stocks in its sector (Healthcare), Emergent BioSolutions Inc has a reliance on debt greater than 60.26% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Emergent BioSolutions Inc? See VIVO, ADMT, NUVA, PBH, and MD.